15
Participants
Start Date
October 31, 2010
Primary Completion Date
April 30, 2011
Study Completion Date
April 30, 2011
Nasal LPS spray
LPS solution (250µl) will be prepared at 10, 100, 300 and 1000µg/ml, 100µl is administered to each nostril, both nostrils will be sprayed. The dose per nostril corresponds to 1, 10, 30 and 100µg.
Experimental: Nasal LPS spray 1µg
LPS solution (250µl) will be prepared at 10, 100, 300 and 1000µg/ml, 100µl is administered to each nostril, both nostrils will be sprayed.
Experimental: Nasal LPS spray 10 µg
LPS solution (250µl) will be prepared at 10, 100, 300 and 1000µg/ml, 100µl is administered to each nostril, both nostrils will be sprayed.
Experimental: Nasal LPS spray 30 µg
LPS solution (250µl) will be prepared at 10, 100, 300 and 1000µg/ml, 100µl is administered to each nostril, both nostrils will be sprayed.
Experimental: Nasal LPS spray 100 µg
LPS solution (250µl) will be prepared at 10, 100, 300 and 1000µg/ml, 100µl is administered to each nostril, both nostrils will be sprayed.
Imperial Clinical Respiratory Research Unit (ICRRU), St Mary's Hospital, Paddington
Collaborators (1)
GlaxoSmithKline
INDUSTRY
Imperial College London
OTHER